Home›Companies›Biotech & Pharma›EpiVario

EpiVario Inc.

Develops potential treatments for people with substance use and other psychiatric disorders.

Updated Nov 9, 2026·Latest SEC filing Oct 13, 2026·Suggest an edit

About EpiVario

EpiVario is a private company based in Philadelphia, Pennsylvania. It has reported $1,277,500 raised in five offerings on Form D since September 2018. Its chief executive is Thomas Kim.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Sep 25, 2026Oct 13, 2026$185,000of $500K target9$20,556Debt, Options, Securities on exerciseRule 506(b)Form D ↗
Jan 8, 2024Jan 16, 2024$125,000of $1.5M target3$41,667Debt, Options, Securities on exerciseRule 506(b)Form D ↗
Aug 26, 2022Sep 12, 2022$135,000of $1.5M target3$45,000Debt, Options, Securities on exerciseRule 506(b)Form D ↗
Jul 30, 2021Aug 3, 2021$233,000of $1.2M target9$25,889Debt, Options, Securities on exerciseRule 506(b)Form D ↗
Sep 12, 2018Sep 21, 2018amended Mar 13, 2020$599,500of $750K target23$26,065Debt, Options, Securities on exerciseRule 506(b)Form D/A ↗3 earlier filings
Total, five offerings$1,277,500

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on EpiVario's Form D filed Oct 13, 2026.

TK
Thomas Kim
President & CEO, director
Also CEO and director at ReEngage Therapeutics.

Earlier filings also listed Yi-Yen Chen (director, last listed Jan 2024) and Michael Dishowitz (director, last listed Sep 2022).

Sources

  1. SECEpiVario Inc. Form D/A, filed Jun 10, 2019
  2. SECEpiVario Inc. Form D/A, filed Dec 12, 2018
  3. SECEpiVario Inc. Form D, filed Sep 21, 2018
  4. SECEpiVario Inc. filing history
  5. PressEpiVario opioid use disorder grant announcement